Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neuroblastoma highly expressed DDX5 stabilizing lncRNA 1 (NHEG1)
- Target
- NHEG1
- Molecular classification
- Long non-coding RNA (lncRNA), Other
01
Overview
Neuroblastoma highly expressed DDX5 stabilizing lncRNA 1 (NHEG1) is a long non-coding RNA prominently upregulated in neuroblastoma tissues, where it influences tumor progression and aggressiveness. It functions by binding to and stabilizing the RNA helicase DDX5, thereby inhibiting its endogenous ubiquitination and proteasomal degradation. This stabilization leads to increased β-catenin activity, promoting cell proliferation and aggressive tumor behavior. NHEG1 also acts as a competitive endogenous RNA for miR-665, which results in derepression of HMGB1, a protein associated with stemness and invasiveness in neuroblastoma. High expression of NHEG1 correlates with poor outcomes and could serve as a prognostic biomarker for neuroblastoma. There are currently no known drugs or drug mechanisms directly targeting NHEG1, nor are there notable safety concerns reported for therapeutic targeting of this molecule.
- Other names
- Neuroblastoma highly expressed 1NHEG1Neuroblastoma highly expressed DDX5 stabilizing lncRNA 1
02
Biological functions
Stabilizes DDX5 protein by preventing ubiquitination and degradationActs as a competitive endogenous RNA (ceRNA) modulating the miR-665/HMGB1 axisPromotes beta-catenin activity, enhancing cell proliferation and tumor aggressivenessRegulates cell proliferation, migration, invasion
03
Disease associations
Cancer (specifically neuroblastoma)
04
Biomarkers
Upregulated NHEG1 expression as prognostic biomarker for unfavorable overall and event-free survival in neuroblastoma
Beyond the preview
Go deeper on Neuroblastoma highly expressed DDX5 stabilizing lncRNA 1 (NHEG1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuroblastoma highly expressed DDX5 stabilizing lncRNA 1 (NHEG1).